Alessia Ligresti

After awarding her MSc degree in Pharmaceutical Chemistry and Technology (University of Naples) in 2001, she joined the Endocannabinoid Research Group in Pozzuoli. In 2005, she awarded a PhD in Pharmaceutical Sciences (University of Naples) and she was visiting researcher at the Department of Biological Science, Allergan Inc. (Irvine, California). After winning a national contest in 2006, she became Research Investigator in 2008 and Senior Scientist in 2010. In 2014, she gained national habilitation as Associate Professor in Biochemistry and Clinical Biochemistry. Since 2004 she works as Preclinical Research Collaborator for GW Pharmaceutical. From 2012 to 2016, she served as Scientific Consultant for Allergan Inc. In 2019, she was visiting researcher at Institute for Research in Biomedicine (Barcelona). She served as Research Project Coordinator and Member of the Supervisory Board of the H2020-MSCA-COFUND “INCIPIT” project, which enabled 35 PhD-positions. She coordinated several national research programs and international private funding initiatives. Co-inventor of 2 patents, she published 119 scientific articles with key discoveries published in leading journals (H-index: 47, Scholar, October 2021). She investigates new therapeutic cannabinoid-based applications for oncometabolic diseases with longstanding experience in developing selective molecules targeting the endocannabinoid system. Recently her interested moved toward mitochondrial bioenergetics and pathophysiology.

1) Kostrzewa M, Mahmoud AM, Verde R, Scotto di Carlo F, Gianfrancesco F, Piscitelli F and Ligresti A. Modulation of Endocannabinoid Tone in Osteoblastic Differentiation of MC3T3-E1 Cells and in Mouse Bone Tissue over Time. Cells (2021) 10(5):1199. doi:10.3390/cells10051199.

2) Cerasuolo M, Maccarinelli F, Coltrini D, Mahmoud AM, Marolda V, Ghedini GC, Rezzola S, Giacomini A, Triggiani L, Kostrzewa M, Verde R, Paris D, Melck D, Presta M, Ligresti A* and Ronca R. Modeling Acquired Resistance to the Second-Generation Androgen Receptor Antagonist Enzalutamide in the TRAMP Model of Prostate Cancer. Cancer Res. 2020 Apr 1;80(7):1564-1577. doi: 10.1158/0008-5472.CAN-18-3637.

3) Mugnaini C, Kostrzewa M, Bryk M, Mahmoud AM, Brizzi A, Lamponi S, Giorgi G, Ferlenghi F, Vacondio F, Maccioni P, Colombo G, Mor M, Starowicz K, Di Marzo V, Ligresti A* and Corelli F. Design, Synthesis, and Physicochemical and Pharmacological Profiling of 7-Hydroxy-5-oxopyrazolo[4,3- b]pyridine-6-carboxamide Derivatives with Antiosteoarthritic Activity In Vivo. J Med Chem (2020) 63(13):7369-7391. doi: 10.1021/acs.jmedchem.0c00595.

4) Ligresti A, De Petrocellis L and Di Marzo V. from phytocannabinoids to cannabinoid receptors and endocannabinoids: pleiotropic physiological and pathological roles through complex pharmacology. Physiol Rev (2016) 96(4):1593-659 doi: 10.1152/physrev.00002.2016.

5) Cerasuolo M, Paris D, Iannotti FA, Melck D, Verde R, Mazzarella E, Motta A and Ligresti A. Neuroendocrine Transdifferentiation in Human Prostate Cancer Cells: An Integrated Approach. Cancer Research (2015) 75(15):2975-86. doi: 10.1158/0008-5472.CAN-14-3830.

1) https://www.webofscience.com/wos/woscc/full-record/WOS:000654721200001

2) https://www.webofscience.com/wos/woscc/full-record/WOS:000522833600017

3) https://www.webofscience.com/wos/woscc/full-record/WOS:000550753700047

4) https://www.webofscience.com/wos/woscc/full-record/WOS:000388263400005

5) https://www.webofscience.com/wos/woscc/full-record/WOS:000359323200003